Terbogrel is primarily investigated for its potential therapeutic applications in the management of cardiovascular diseases. It functions as a thromboxane synthase inhibitor and thromboxane receptor antagonist, making it effective in preventing platelet aggregation and vasoconstriction. This dual mechanism of action suggests its utility in conditions like myocardial infarction, unstable angina, and other thrombotic disorders. By reducing the formation of thromboxane A2, it helps improve blood flow and decrease the risk of clot formation in patients with arterial diseases. Additionally, its antiplatelet properties make it a candidate for use in conjunction with other anticoagulant therapies to enhance efficacy in preventing cardiovascular events. Research continues to explore its broader applications in treating pulmonary hypertension and other vascular disorders.